MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Kymera Therapeutics Inc

Ouvert

SecteurSoins de santé

33.2 2.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.02

Max

33.81

Chiffres clés

By Trading Economics

Revenu

-8.3M

-71M

Ventes

3.7M

7.4M

BPA

-0.89

Marge bénéficiaire

-956.884

Employés

188

EBITDA

-8.3M

-69M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+80.98% upside

Dividendes

By Dow Jones

Prochains Résultats

9 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-523M

1.8B

Ouverture précédente

31.05

Clôture précédente

33.2

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Kymera Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 nov. 2024, 03:00 UTC

Actualités

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 juil. 2024, 09:05 UTC

Actualités

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Comparaison

Variation de prix

Kymera Therapeutics Inc prévision

Objectif de Prix

By TipRanks

80.98% hausse

Prévisions sur 12 Mois

Moyen 55.56 USD  80.98%

Haut 72 USD

Bas 49 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

25.43 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Strong Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.